Home › Atopic Dermatitis (Eczema) › NCT07746427
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Outcomes of a Digital Mindfulness Meditation App-Based Intervention in Adolescents With Moderate to Severe Atopic Dermatitis (MIND-AD)
Who can join
Ages 13 to 17 · All sexes
Full eligibility criteria
Inclusion Criteria * Adolescents age 13-17 years. * Atopic dermatitis refractory to standard topical treatment including topical steroids or topical calcineurin inhibitors. * Moderate to severe atopic dermatitis via PO-SCORAD score on enrollment. Exclusion Criteria * Started on a biologic agent (i.e. dupxient) within the past 3 months. * Mild atopic dermatitis via PO-SCORAD score on enrollment.
About the study
Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesize that regular use of a digital mindfulness meditation app will improve disease control and quality of life in adolescents with moderate to severe atopic dermatitis based on validated survey measures.
What is being tested
- Digital App Mindfulness Meditation (behavioral)
- Mindfulness Meditation Sheet (behavioral)
Sponsor: Weill Medical College of Cornell University · Participants: 40 · Started: Aug 15, 2026
Contact the study team
- Dana A O'Toole, MD · Phone: 646-962-3410
Official record on ClinicalTrials.gov — NCT07746427
Locations in the U.S.
| New York | Columbia University Irving Medical Center, New York Weill Cornell Medicine, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.